View all Medical Crossfire CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Resources>

PER Pulse™ Recaps highlight key points presented in Medical Crossfire®: Clinical Application of Biomarker Testing in NSCLC. The first of 3 PER Pulse™ Recaps from this Medical Crossfire® focuses on randomized data comparing immunotherapy to docetaxel in patients with previously treated, advanced NSCLC. The second of 3 PER Pulse™ Recaps from this Medical Crossfire® focuses on panel discussion of case scenarios in patients with leptomeningeal disease or mutations in the epidermal growth factor receptor (EGFR) gene. The third of 3 PER Pulse™ Recaps from this Medical Crossfire® focuses on panel discussion of case scenarios in patients undergoing testing for PD-L1 or who have had a solid organ transplant.


Acknowledgment of Commercial Support

This activity is supported by an educational grant from Merck Sharp & Dohme Corp.


Medical Crossfire®: Clinical Application of Biomarker Testing in NSCLC


Release Date: August 2, 2016
Expiration Date: August 2, 2017
Media: Internet - based

Activity Overview

This Medical Crossfire® filmed panel discussion aims to ensure the knowledge and ability of oncology healthcare professionals to apply evidence on immuno-oncology strategies and emerging biomarker information that can assist them to personalize care for their patients with advanced NSCLC. Medical Crossfire® brings together internationally known experts for guidance, interpretation and opinions on current clinical trial data and application to practice. The panel will review patient scenarios, reflect on how they might handle particular cases, integrate relevant evidence into real-world treatment, and compare their practices with those of other experts in the field, and peers, as a vehicle that enhances learning of key emerging treatment concepts. This panel discussion will be filmed and endured online in PER’s legacy Medical Crossfire® multi-module format, available on www.gotoper.com.

CME Activity Table of Contents

  • Introduction and Overview of Key Clinical Trials
  • Case-Based Discussions

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This activity is intended for medical oncologists, nurses, pathologists, pulmonologists, interventional radiologists, thoracic surgeons, and other health-care professionals involved in the care of patients with advanced NSCLC may also participate.


Educational Objectives

At the conclusion of this activity, you should be better prepared to:
  • Provide a historical context for the development of immuno-oncology strategies to manage advanced NSCLC including landmark trials that evaluated these compounds
  • Discuss methods to individualize immuno-oncology strategies including evolving evidence on the role of biomarkers such as PD-L1 and its interpretation
  • Apply evidence on biomarkers, treatment efficacy/tolerability, and patient performance status to optimize personalized approaches with immuno-oncology strategies in the care of patients with advanced NSCLC


Faculty, Staff, and Planners' Disclosures

Program Chair

Naiyer Rizvi, MD
Director, Thoracic Oncology 
Director, Immunotherapeutics Price 
Chair, Clinical Translational Research 
Columbia University Medical Center 
New York, NY


Disclosure: Consultant: AstraZeneca, Roche, Novartis, and Merck; Stock/Shareholder: Gritstone Oncology


Faculty

Edward Garon, MD
Hematology & Oncology 
Ronald Reagan UCLA Medical Center
UCLA Medical Center
Santa Monica, CA


Disclosure: Grant/Research Support: AstraZeneca, Merck, BMS, Eli Lily, Pfizer, Novartis, and Genentech (related to clinical trials)
 

Leena Gandhi, MD
Dana-Farber Cancer Institute
Harvard University
Assistant Professor of Medicine
Boston, MA


Disclosure: Grant/Research Support: BMS; Consultant: Scientific Advisory Board- Merck, AbbVie, Pfizer, Astra-Zeneca, Genentech/Roche; Other Support (Honoraria): Merck
 

Roy Herbst, MD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT

Disclosure: Scientific Advisory Board: Biothera, Diatech, and Koltan; Consulting: AstraZeneca, Eli Lily, Genentech/Roche, Merck, and Pfizer; Clinical Trials Support/Grant: Genentech, and Merck
 

 

The following individuals have no relevant financial relationships with commercial interests:
The staff of PER®, LLC


Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.


Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.


Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise




Calendar of Events
Filter By